313 related articles for article (PubMed ID: 32995480)
1. Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer.
Berry JTL; Muñoz LE; Rodríguez Stewart RM; Selvaraj P; Mainou BA
Mol Ther Oncolytics; 2020 Sep; 18():556-572. PubMed ID: 32995480
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Rodríguez Stewart RM; Berry JTL; Berger AK; Yoon SB; Hirsch AL; Guberman JA; Patel NB; Tharp GK; Bosinger SE; Mainou BA
J Virol; 2019 Dec; 93(23):. PubMed ID: 31511390
[TBL] [Abstract][Full Text] [Related]
3. Noncanonical Cell Death Induction by Reassortant Reovirus.
Rodríguez Stewart RM; Raghuram V; Berry JTL; Joshi GN; Mainou BA
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847857
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
5. Necroptotic virotherapy of oncolytic alphavirus M1 cooperated with Doxorubicin displays promising therapeutic efficacy in TNBC.
Zhang J; Liu Y; Tan J; Zhang Y; Wong CW; Lin Z; Liu X; Sander M; Yang X; Liang L; Song D; Dan J; Zhou Y; Cai J; Lin Y; Liang J; Hu J; Yan G; Zhu W
Oncogene; 2021 Jul; 40(29):4783-4795. PubMed ID: 34155344
[TBL] [Abstract][Full Text] [Related]
6. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
[TBL] [Abstract][Full Text] [Related]
7. Modulation of Reoviral Cytolysis (I): Combination Therapeutics.
Mori Y; Nishikawa SG; Fratiloiu AR; Tsutsui M; Kataoka H; Joh T; Johnston RN
Viruses; 2023 Jun; 15(7):. PubMed ID: 37515160
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-Loaded Platelet Decoys for Enhanced Chemoimmunotherapy Against Triple-Negative Breast Cancer in Mice Model.
Dong H; Gao M; Lu L; Gui R; Fu Y
Int J Nanomedicine; 2023; 18():3577-3593. PubMed ID: 37409026
[TBL] [Abstract][Full Text] [Related]
9. Reduction of virion-associated σ1 fibers on oncolytic reovirus variants promotes adaptation toward tumorigenic cells.
Mohamed A; Teicher C; Haefliger S; Shmulevitz M
J Virol; 2015 Apr; 89(8):4319-34. PubMed ID: 25653434
[TBL] [Abstract][Full Text] [Related]
10. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
Kumar V; Giacomantonio MA; Gujar S
Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma.
Cooper T; Biron VL; Fast D; Tam R; Carey T; Shmulevitz M; Seikaly H
J Otolaryngol Head Neck Surg; 2015 Feb; 44(1):8. PubMed ID: 25890191
[TBL] [Abstract][Full Text] [Related]
12. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell-Based Immunotherapies.
Groeneveldt C; Kinderman P; Griffioen L; Rensing O; Labrie C; van den Wollenberg DJM; Hoeben RC; Coffey M; Loghmani H; Verdegaal EME; Welters MJP; van der Burg SH; van Hall T; van Montfoort N
Cancer Immunol Res; 2024 Mar; 12(3):334-349. PubMed ID: 38194598
[TBL] [Abstract][Full Text] [Related]
14. Doxorubicin-polyglycerol-nanodiamond conjugate is a cytostatic agent that evades chemoresistance and reverses cancer-induced immunosuppression in triple-negative breast cancer.
Yuan SJ; Xu YH; Wang C; An HC; Xu HZ; Li K; Komatsu N; Zhao L; Chen X
J Nanobiotechnology; 2019 Oct; 17(1):110. PubMed ID: 31623629
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery.
Kemp V; Dautzenberg IJC; Limpens RW; van den Wollenberg DJM; Hoeben RC
Viruses; 2017 Sep; 9(10):. PubMed ID: 28934149
[TBL] [Abstract][Full Text] [Related]
16. Macrophage-Derived Extracellular Vesicles as Drug Delivery Systems for Triple Negative Breast Cancer (TNBC) Therapy.
Haney MJ; Zhao Y; Jin YS; Li SM; Bago JR; Klyachko NL; Kabanov AV; Batrakova EV
J Neuroimmune Pharmacol; 2020 Sep; 15(3):487-500. PubMed ID: 31722094
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic Viral Therapy Using Reovirus.
Thirukkumaran C; Morris DG
Methods Mol Biol; 2015; 1317():187-223. PubMed ID: 26072409
[TBL] [Abstract][Full Text] [Related]
18. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway.
Wu L; Ding W; Wang X; Li X; Yang J
Genes Genomics; 2023 Oct; 45(10):1329-1338. PubMed ID: 37634232
[TBL] [Abstract][Full Text] [Related]
19. Polyglutamic acid-based crosslinked doxorubicin nanogels as an anti-metastatic treatment for triple negative breast cancer.
Duro-Castano A; Sousa-Herves A; Armiñán A; Charbonnier D; Arroyo-Crespo JJ; Wedepohl S; Calderón M; Vicent MJ
J Control Release; 2021 Apr; 332():10-20. PubMed ID: 33587988
[TBL] [Abstract][Full Text] [Related]
20. Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer.
Zeng W; Luo Y; Gan D; Zhang Y; Deng H; Liu G
Front Bioeng Biotechnol; 2023; 11():1271420. PubMed ID: 38047286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
